Roche Launches Axelios Gene Sequencer to Challenge Illumina's Market Dominance

Roche launched its Axelios gene sequencer on June 29, 2026, targeting Illumina's 70% share of the $7.3 billion next-generation sequencing market. Priced at $750,000—undercutting Illumina's NovaSeq X by up to $500,000—Axelios uses nanopore technology to analyse DNA in near real time. Roche aims to sell 100 machines in year one, building toward 1 billion Swiss francs in annual sales, backed by partnerships with 10x Genomics and Google DeepVariant.

Axelios gene sequencer launch

• ▪Roche launched its Axelios gene sequencer on June 29, 2026, to challenge Illumina's leadership in next-generation sequencing.
• ▪The Axelios platform is designed to rapidly read and analyse DNA at scale, supporting applications from disease research to drug development.
• ▪Roche's Axelios launch is limited to academic and research-focused facilities.

Nanopore sequencing technology

• ▪Axelios converts DNA or ribonucleic acid (RNA) into longer molecules that are easier to read, then passes them through tiny pores on a reusable chip to generate genetic data.
• ▪Axelios generates genetic data that can be analysed in near real time, unlike traditional short-read sequencing systems.

Competitive pricing strategy

• ▪The upfront price of the instrument is secondary to the recurring cost of supplies such as chemical reagents, which can add up to millions of dollars over the lifespan of the machine.
• ▪Roche's Axelios is priced at $750,000 in the United States, compared to Illumina's NovaSeq X machines which list at roughly $985,000 to $1.25 million.

Illumina market dominance

• ▪Illumina holds approximately 70% of the next-generation sequencing systems market, valued at about $7.3 billion.
• ▪Roche's failed $6.8 billion hostile bid to acquire Illumina occurred more than a decade before the Axelios launch.

First-year sales targets

• ▪Roche's first-year target of 100 machines will lay the foundation for a future blockbuster franchise generating over 1 billion Swiss francs ($1.1 billion) in annual sales over the long term.
• ▪Roche aims to sell about 100 Axelios machines in the first year.
• ▪Vontobel analyst Stefan Schneider said the first-year target was achievable with high certainty given Roche's commercial scale, but noted that diagnostic launches typically ramp up more slowly than medicines due to institutional tender processes.

Strategic partnership ecosystem

• ▪Roche has partnered with 10x Genomics and Google DeepVariant for data analysis to support the Axelios platform.
• ▪Broad Clinical Labs and the Hartwig Medical Foundation provided early platform validation for Axelios to ease adoption.

1 source